SuperworthNRC Health EPS NRC
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $0.25
- Latest quarter, Q2 FY26
- −$0.15
- Fiscal year 2025
- $0.50
- −52% on the year before
NRC Health's earnings per share was $0.25 over the twelve months to Jun 30, 2026, down 67% on a year earlier.
In its latest quarter, Q2 FY26, it was −$0.15.
Over the five fiscal years to FY2025 it shrank 19% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.50 | −52% |
| FY2024 | $1.05 | −16% |
| FY2023 | $1.25 | −2% |
| FY2022 | $1.27 | −14% |
| FY2021 | $1.47 | +1% |
| FY2020 | $1.45 | +15% |
| FY2019 | $1.26 | +22% |
| FY2018 | $1.03 | +54% |
| FY2017 | $0.67 | +8% |
| FY2016 | $0.62 | +11% |
| FY2015 | $0.56 | +6% |
| FY2014 | $0.53 | +15% |
| FY2013 | $0.46 | −50% |
| FY2012 | $0.92 | −46% |
| FY2011 | $1.70 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.15 | n/a | $0.25 | |
| Q1 FY26 | $0.14 | −44% | $0.39 | |
| Q4 FY25 | $0.08 | −71% | $0.50 | |
| Q3 FY25 | $0.18 | −25% | $0.70 | |
| Q2 FY25 | −$0.01 | −104% | $0.76 | |
| Q1 FY25 | $0.25 | −7% | $1.03 | |
| Q4 FY24 | $0.28 | −22% | $1.05 | |
| Q3 FY24 | $0.24 | −25% | $1.13 | |
| Q2 FY24 | $0.26 | −10% | $1.21 | |
| Q1 FY24 | $0.27 | −4% | $1.24 | |
| Q4 FY23 | $0.36 | +33% | $1.25 | |
| Q3 FY23 | $0.32 | −3% | $1.16 |
Against its peers
Companies in Medical - Diagnostics & Research nearest NRC Health's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| NRCNRC Health | $0.25 | −67% a year |
| ICCCImmucell | $0.08 | −58% a year |
| CDNACareDx | $2.07 | +116% a year |
| VCYTVeracyte | $1.40 | +324% a year |
| Peer median | $1.40 |
Where NRC Health ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on NRC Health
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.